Driven by the current interest in multitarget approaches in cancer treatment, in the context of angiogenesis, we reasoned that by combining the inhibition of αvβ3 and MMP2 we could deliver a synergistic blockade of tumor cell migration, invasion and metastasis. The gene discussed is MMP2; the disease is cancer.